HERTFORDSHIRE, England and
PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL), today announced the U.S. launch of
Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a
generic version of Pfizer's Pristiq® Tablets. Mylan received final
approval from the U.S. Food and Drug Administration (FDA) for its
Abbreviated New Drug Application (ANDA) for this product, which is
indicated for the treatment of major depressive disorder. (1)
Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, had
U.S. sales of approximately $853
million for the 12 months ending January 31, 2017, according to IMS Health.
Currently, Mylan has 241 ANDAs pending FDA approval representing
approximately $100.9 billion in
annual brand sales, according to IMS Health. Forty-five of these
pending ANDAs are potential first-to-file opportunities,
representing $39 billion in annual
brand sales, for the 12 months ending December 31, 2016, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of approximately 7,500 marketed products around the
world, including antiretroviral therapies on which approximately
50% of people being treated for HIV/AIDS in the developing world
depend. We market our products in more than 165 countries and
territories. We are one of the world's largest producers of active
pharmaceutical ingredients. Every member of our more than
35,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
(1) Antidepressants can increase the risk of suicidal thinking
and behavior in children, adolescents and young adults. Monitor for
worsening and emergence of suicidal thoughts and behaviors. This
medicine is not approved for use in pediatric patients.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-pristiq-tablets-300421739.html
SOURCE Mylan N.V.